Lundbeck gears up as Alzheimer's agitation approval looks attainable
Anticipating a US market authorization for a treatment candidate for Alzheimer’s agitation, the Danish pharmaceutical firm is getting things in order – all due to the summer’s compelling phase III evidence.
by christopher due karlsson, translated by daniel pedersen
Over the summer, Danish pharmaceutical firm Lundbeck and partner Otsuka Pharmaceutical received some very positive phase III data for their co-developed candidate, brexpiprazole, as a potential treatment for Alzheimer’s agitation.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck raises 2022 guidance
For subscribers
